PMID- 17963263
OWN - NLM
STAT- MEDLINE
DCOM- 20080122
LR  - 20220331
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 111
IP  - 6
DP  - 2007 Dec 25
TI  - Combined morphologic and fluorescence in situ hybridization analysis of voided 
      urine samples for the detection and follow-up of bladder cancer in patients with 
      benign urine cytology.
PG  - 517-24
AB  - BACKGROUND: Bladder cancer is among the 5 most common malignancies worldwide. 
      Patients with bladder cancer are closely followed with periodic cystoscopies and 
      urine cytology analyses due to the significant risk of tumor recurrence. The 
      UroVysion fluorescence in situ hybridization (FISH) test demonstrated higher 
      sensitivity over urine cytology in detecting bladder cancer by most comparative 
      studies. METHODS: In the current study, the diagnostic usefulness of a combined 
      cytology and FISH analysis approach was tested using the Duet automatic scanning 
      system in patients with benign urine cytology who were being monitored for 
      recurrent urothelial carcinoma or being assessed for various urologic symptoms. 
      RESULTS: By combining the benefits of conventional cytology with molecular 
      diagnostics, a more sensitive detection of bladder cancer was attained. All 
      patients who had positive cystoscopy concomitantly with urine sampling were 
      detected by combined analysis. Additional patients that developed transitional 
      cell carcinoma during a follow-up period of 24 months had a previous positive 
      result on combined analysis. Only 2 patients with a negative combined analysis 
      result presented with late disease recurrence (20 months and 22 months, 
      respectively, after the negative test). Therefore, negative combined analysis was 
      found to be predictive of a lack of disease recurrence for at least 12 months. In 
      this timeframe, the overall sensitivity, specificity, negative predictive value 
      (NPV), and positive predictive values of the combined analysis test were 100%, 
      65%, 100%, and 44%, respectively. CONCLUSIONS: Given the absolute sensitivity and 
      NPV of the combined analysis test, the management of patients with a negative 
      combined analysis result might be revised and allow for more flexible assessment 
      and management of bladder cancer patients relying more on urine bound tests.
FAU - Daniely, Michal
AU  - Daniely M
AD  - BioView Ltd, Rehovot, Israel. michal@bioview.co.il
FAU - Rona, Roni
AU  - Rona R
FAU - Kaplan, Tal
AU  - Kaplan T
FAU - Olsfanger, Shirley
AU  - Olsfanger S
FAU - Elboim, Lea
AU  - Elboim L
FAU - Freiberger, Avner
AU  - Freiberger A
FAU - Lew, Sylvia
AU  - Lew S
FAU - Leibovitch, Ilan
AU  - Leibovitch I
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
MH  - Cytodiagnosis
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Neoplasm Recurrence, Local/diagnosis
MH  - Sensitivity and Specificity
MH  - Urinary Bladder Neoplasms/*pathology/*urine
MH  - Urine/*cytology
EDAT- 2007/10/30 09:00
MHDA- 2008/01/23 09:00
CRDT- 2007/10/30 09:00
PHST- 2007/10/30 09:00 [pubmed]
PHST- 2008/01/23 09:00 [medline]
PHST- 2007/10/30 09:00 [entrez]
AID - 10.1002/cncr.23119 [doi]
PST - ppublish
SO  - Cancer. 2007 Dec 25;111(6):517-24. doi: 10.1002/cncr.23119.